55 results about "Interventricular septum" patented technology

The invention relates to a simulation-based target removal area determination method and device. The method comprises the following steps: acquiring a heart simulation model and corresponding blood flow field information; according to the left heart lumen model and the blood flow field information, determining a first target area in the ventricular septum model; stress calculation is carried out according to the ventricular septum model, and a second target area in the ventricular septum model is determined; determining an initial target area according to the first target area and the second target area; according to the ventricular septum model, determining the thickness range of the initial target area at the end of contraction; determining a target cutting thickness according to a preset basic thickness and a thickness range; according to the heart simulation model, the initial target area, the target resection thickness and the blood flow field information, a first target resection area is determined. By adopting the method, the cardiac muscle tissue area needing to be cut off can be accurately determined.

A system for percutaneous ventriculoplasty. Anchors can be placed in the ventricular septum and the ventricular wall. Sutures tethered to the anchors can be tensioned to reduce the size of a dilated left ventricle. Multiple anchors can be positioned in the ventricular wall and the sutures can be independently tensioned to allow tailored treatment of the dilated ventricle.

A biostimulator and a biostimulator system for septal pacing, is described. The biostimulator includes an articulation to allow an electrode axis of a pacing electrode to be directed differently than a housing axis of a housing. The housing contains electrical circuitry that is electrically connected to the pacing electrode. The differently directed axes allow the pacing electrode to affix to target tissue of an interventricular septal wall of a heart when the housing of the biostimulator is located near an apex of the heart. The articulation can include a flexible portion of an extension, a hinge, or a tether. Other embodiments are also described and claimed.

This invention discloses a method for preparing a simulated heart model and the simulated heart model itself. The method for preparing the simulated heart model includes: dividing a digital heart model into two parts along its coronal plane; preparing corresponding molding molds according to the structural characteristics of the two parts, each molding mold including an outer molding mold and an inner cavity molding mold; applying silicone to the molding surfaces of the outer molding mold and the inner cavity molding mold to form the endocardium and epicardium; applying silicone to the portion of the inner cavity molding mold used for molding the valve to form the valve; assembling the outer molding mold and the inner cavity molding mold to form a cavity; sequentially injecting silicone of corresponding hardness into the regions of the cavity used for molding the atrial myocardium, interatrial septal myocardium, ventricular myocardium, and interventricular septal myocardium to form heart model halves; and bonding the heart model halves corresponding to the two molding molds together to obtain the simulated heart model.

The utility model relates to the technical field of ventricular septum perforation plugging devices, and discloses a novel ventricular septum perforation plugging device which comprises a fixing column and a first disc-shaped net arranged on the outer side of the fixing column, a connecting waist part is further arranged on the outer side of the fixing column, and the connecting waist part is connected with the first disc-shaped net. A second disc-shaped net is arranged on the side, away from the first disc-shaped net, of the connecting waist part, an end is arranged on one side of the second disc-shaped net, and before use, a small screw at the front end of a transmission steel cable is used for being connected with the end, so that the whole compressed plugging device can be transmitted to a heart defect part through a pipeline; the first disc-shaped net and the second disc-shaped net are used for blocking, the defect part can be blocked, the biological membrane can make contact with the heart defect part, the sealing performance is further improved, meanwhile, the polyurethane coating has certain flexibility, friction between the polyurethane coating and the heart defect part is effectively reduced, and the service life of the heart defect part is prolonged. The heparin coating can reduce the risk of thrombus formation, so that the use risk is reduced.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

This invention discloses a method for predicting sudden cardiac death based on forensic autopsy data using machine learning and its forensic applications, belonging to the fields of machine learning, statistics, and forensic identification. This invention provides a method for screening independent predictors of forensic diagnosis of sudden cardiac death using LASSO regression and logistic regression. Using 10-fold cross-validation, the method selects the minimum lambda(λ) to identify 14 risk factors. Logistic regression ultimately identifies 9 independent predictors, including age, heart weight, left ventricular wall thickness, right ventricular wall thickness, interventricular septum thickness, aortic valve circumference, mitral valve circumference, liver weight, and left kidney weight. A nomogram and a web-based calculator are constructed for predicting sudden cardiac death in forensic practice, thereby determining sudden cardiac death using objective indicators. This method has not been reported worldwide.

The invention discloses a first-aid device for relieving SAM symptoms, which comprises a guide puncture sheathing canal, a first-aid device is arranged in the guide puncture sheathing canal, the first-aid device comprises a hollow sheathing canal of which the top end is an inclined plane, a channel is formed in the wall of the hollow sheathing canal, a jacking component is mounted in the hollow sheathing canal, and a propelling component is arranged at the bottom end of the hollow sheathing canal. The bottom end of the jacking assembly is connected with the top end of the pushing assembly, a main supporting strip and an auxiliary supporting strip of the jacking assembly can open and close the elastic umbrella cover, the pushing assembly is used for pushing the jacking assembly forwards to enable the jacking assembly to stretch out of the top end of the hollow sheathing canal to open the elastic umbrella cover, an anti-falling plate is further arranged at the bottom end of the hollow sheathing canal, and the pushing assembly is inserted into the anti-falling plate. The device is reasonable in structure and easy and convenient to operate, is applied to the first-aid operation of the SAM symptom patient, and can be used for rapidly jacking up the mitral valve anterior lobe to be separated from the ventricular septum, widening the left ventricular outflow tract and win time for the subsequent treatment of the patient.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating ventricular remodeling and a preparation method thereof. The traditional Chinese medicine composition for preventing and treating ventricular remodeling is prepared from the following raw materials: 25 to 35 parts of radix astragali seu hedysari, 10 to 15 parts of cassia twig, 10 to 15 parts of peach kernel, 12 to 18 parts of flos carthami and 7 to 11 parts of semen lepidii. According to the traditional Chinese medicine composition, the left ventricular posterior wall thickness, the ventricular septum thickness and the left ventricular end diastolic inner diameter are obviously increased, the left ventricular end systolic inner diameter, the left ventricular mass index and the right ventricular mass index are obviously reduced, and it is prompted that the traditional Chinese medicine composition can inhibit ventricular remodeling of rats suffering from ischemic cardiomyopathy.

A system for percutaneous ventriculoplasty. Anchors can be placed in the ventricular septum and the ventricular wall. Sutures tethered to the anchors can be tensioned to reduce the size of a dilated left ventricle. Multiple anchors can be positioned in the ventricular wall and the sutures can be independently tensioned to allow tailored treatment of the dilated ventricle.

Mitral regurgitation can be reduced by creating one passageway between the right atrium and left ventricle in a portion of the tricuspid annulus just above the ventricular septum and another passageway through the outer wall of the left ventricle near at least one of the left ventricular papillary muscles. A support rod is positioned in the right atrium in contact with the septal portion of the tricuspid annulus, and a support plate is positioned adjacent to the second passageway and against the outer wall of the left ventricle. The support plate is pulled toward the support rod using a tether that extends between the first support plate and the support rod, passes through both passageways, and is under tension. The tension in the tether moves the root of the tendon closer to the mitral valve, which reduces mitral regurgitation.

This invention relates to a biodegradable cardiac occluder for bilateral ventricular septal defect closure, comprising a first disc-shaped mesh, a second disc-shaped mesh, a tubular portion, and a rivetless flat-face connector. The tubular portion connects the first and second disc-shaped meshes. The rivetless flat-face connector includes a delivery disc and threaded holes. The delivery disc has mesh fixing holes for connecting the first disc-shaped mesh and the delivery disc. A steel cable can be connected to the occluder via the threads and threaded holes. This invention uses a small disc to replace rivets, achieving both re-delivery and the goal of reducing thrombosis incidence through rivetless design. The rivetless flat-face connector can be biodegradable or non-biodegradable. During processing, it is woven into the mesh body, making it convenient, safe, and quick.

An implantable assembly suitable for remodeling a chamber of a heart in a patient is disclosed. The assembly is implanted with a tool having a tool proximal portion and a distal portion. The assembly includes a mobile anchor including an abutment portion adapted to abut against a wall of the chamber of the heart and a tether portion rotatably coupled to the abutment portion. Each of the abutment portion and the tether portion are configured to be independently coupled from the tool. The assembly further includes an interventricular septum anchor for coupling to a septum of the heart and a tether having a working portion extending between the mobile anchor and the septum anchor having a first length and a tether proximal portion having a second length. The abutment portion is releasably locked to the tether portion and is configured such that a preselected torque applied to the tether portion of the mobile anchor unlocks and causes relative rotation of the tether portion relative to the abutment portion.

A detachable leadless pacemaker system for cardiac conduction bundle pacing is disclosed. The system includes a detachable leadless pacemaker and a passive leadless pacemaker. A hook-shape side electrode is inserted into a ventricular septum for cardiac conduction bundle pacing. The detachable leadless pacemaker may be arranged in a ventricle, and the passive leadless pacemaker may be arranged in an atrium, so as to realize dual-chamber pacing both in the ventricle and in the atrium. The detachable leadless pacemaker is coupled with the passive leadless pacemaker by an anti-tension reinforced wire, which is used for pulling back the detachable leadless pacemaker to a new position.

The present invention proposes a hypertrophic obstructive cardiomyopathy ablation device, which includes an adjustable bend sheath assembly, a mapping catheter, an ablation needle assembly, and an ultrasound assembly. The mapping catheter is inserted into the adjustable bend sheath assembly and can be moved along the axial direction of the adjustable bend sheath assembly to the distal end of the adjustable bend sheath assembly to exit. The mapping catheter is used to map the heart, and the ablation needle assembly is used to chemically ablate the hypertrophic portion of the ventricular septum of the right ventricle. The ultrasound assembly can be moved to the distal end of the adjustable bend sheath assembly to exit, and the ultrasound assembly is used to monitor the position of the ablation needle assembly. The hypertrophic obstructive cardiomyopathy ablation device integrates the ultrasound assembly, the ablation needle assembly, and the mapping catheter. Under the real-time image guidance of the ultrasound assembly, the ablation needle assembly is controlled to chemically ablate the hypertrophic portion of the myocardium, ensuring the accuracy of the ablation position and the ablation depth. Under the premise of ablation safety, alcohol ablation is given to cause myocardial necrosis in the deep layer of the ventricular septum to relieve the obstruction.

The invention discloses a direction-adjustable bending radiofrequency ablation electrode needle which comprises an ablation needle handle, a coaxial sheath, a steering electrode needle, an electrode wire, an outflow tube, an inflow tube and a negative electrode patch. The steering electrode needle is arranged in an inner cavity of the ablation needle handle and the coaxial sheath, the steering electrode needle made of shape memory alloy and the coaxial sheath are matched in a push-pull mode to synchronously adjust and control the length and the angle of the electrode needle, the needle point of the electrode needle is coated with the conductive nanometer coating, protein, tissue and the like are prevented from being adhered to the needle point, and carbonization is reduced. The direction of the ablation electrode needle and the length of the working end can be adjusted and controlled, a safer, more effective and more stable operation ablation treatment mode is achieved through the conductive ceramic coating on the needle tip part, the electrode needle can be suitable for Liwen operation type treatment of complex hypertrophic cardiomyopathy ventricular septal parting, and the safety, effectiveness and operability of the Liwen operation type operation process can be improved.

This application provides an ultrasound cardiac dynamic monitoring system and method, relating to the field of ultrasound cardiac function dynamic monitoring technology. The system includes: a patch-type ultrasound probe, a hydrogel patch, a wearable hardware module, and a cardiac function analysis module. The cardiac function analysis module is configured to: receive the ultrasound image; determine a target sampling line in the ultrasound image based on a reinforcement learning model; control the wearable hardware module to acquire M-mode images along the target sampling line; input the M-mode images into a deep learning model to output the key point positions of the left ventricular septum and the left ventricular posterior wall at end-diastole and end-systole based on the deep learning model; calculate the left ventricular ejection fraction (LVEF) based on the LVEF and the key point positions; the LVEF represents the dynamic monitoring and detection results of cardiac function. This system can improve the effectiveness and accuracy of dynamic cardiac monitoring.

A medical dilator is provided. The medical dilator includes an elongated member having a distal end and a proximal end with a lumen therebetween, and a reinforcing member that is shapeable and configured to provide rigidity and support for an atrioventricular septal puncture system.

The invention discloses myocardial biopsy forceps capable of being bent in two directions, and relates to the technical field of medical instruments, the myocardial biopsy forceps comprise a forceps head assembly and a handle assembly, the handle assembly comprises a bending adjusting device, the bending adjusting device is used for driving a bending adjusting pipe body to bend, and at least two pull wires are arranged in the bending adjusting pipe body; the bend adjusting device comprises a rotating mechanism and a winding mechanism connected with the rotating mechanism, the winding mechanism is connected with two stay wires, the rotating mechanism is rotated forwards to drive the winding mechanism to rotate, and the bend adjusting pipe body is driven to bend forwards through the two stay wires; the rotating mechanism is rotated reversely to drive the winding mechanism to rotate, the bend adjusting pipe body is driven by the two stay wires to bend reversely, the bend adjusting device is operated to rotate to control the bend adjusting pipe body to conduct continuous bend adjusting towards one side or reversely, stress of the stay wires is even, the tong head assembly can be more easily and accurately aligned with the ventricular septum, risks in the alignment process are reduced, and the alignment efficiency is improved. Therefore, the bend adjusting pipe body instantly generates large bending to collide with the ventricular septum, and iatrogenic injury is caused.

The invention relates to the field of medical image processing, in particular to a congenital heart disease four-dimensional echocardiogram dynamic segmentation system, which acquires four-dimensional echocardiogram data of a fetal heart through an image acquisition module, corrects fetal movement artifacts by an optical flow field correction module by using an optical flow field time sequence analysis technology, improves the image quality, and improves the segmentation accuracy of the fetal movement artifacts. The heart structure time sequence alignment module is used for aligning a heart structure and extracting a ventricular septal defect area through a multi-scale similarity transformation strategy, the defect analysis module is used for calculating the edge line diameter and the shunt direction of a defect part and generating defect parameter information, and the result output module is used for generating a congenital heart disease screening report. And a foundation is laid for subsequent analysis, and the defect part is kept at a stable position in a time sequence by accurately aligning the heart structure, so that accurate analysis is facilitated.

Systems, devices, and methods for delivering conductive nanomaterials to a target location in a patient's heart to affect the patient's heart conduction system, such as delivering conductive nanomaterials into the ventricular septum of the patient's heart to improve an impaired heart conduction pathway, such as the left bundle branch.

The invention relates to a lead device comprising a lead tip having a distal fixation helix for fixing the lead tip at tissue of a patient, such as heart tissue, in particular ventricular septal tissue, where the fixation helix comprises a cutting portion for cutting the lead tip into the tissue when the fixation helix is screwed into the tissue. In addition to puncturing through the distal tip of the stationary helix (30), the tissue is cut in the circumferential direction of the stationary helix to assist in longitudinal insertion of the lead tip having the stationary helix into the tissue. Therefore, since the tissue is pre-cut in the circumferential direction at and / or around and / or within the fixation helix during the operation of screwing in the tissue, insertion and longitudinal advancement of the lead tip into the tissue can be facilitated and smoothed.

A method of operating a cardiac rhythm management (CRM) system includes: measuring a baseline PR interval of cardiac depolarization; measuring one or both of the heart sound and the heart depolarized QRS width; delivering pacing stimulation according to atrial sensing of a ventricular pacing interval (AsVp interval), and measuring one or both of a heart sound and a QRS width of the AsVp interval, where the pacing stimulation is delivered using a conducted system pacing (CSP) vector comprising electrodes positioned in the interventricular septum; delivering a pacing stimulus according to an atrial pacing to ventricular pacing interval (ApVp interval) and measuring one or both of a heart sound and a QRS width of the ApVp interval; and generating a recommended atrial-to-ventricular delay setting for the CSP based on one or both of the measured heart sound and the QRS width.

The present invention provides a method, device, and ultrasonic imaging device for determining left ventricular parameters. The method comprises: collecting two-dimensional ultrasonic cardiac data of a target subject over a continuous period of time, the continuous period being greater than one cardiac cycle, the two-dimensional ultrasonic cardiac data comprising multiple frames of two-dimensional ultrasonic cardiac images; determining multiple target frame images from the multiple frames of two-dimensional ultrasonic cardiac images, the target frame images comprising multiple frames of end-diastolic images corresponding to the end-diastolic phase and multiple frames of end-systolic images corresponding to the end-systolic phase; performing image segmentation on the target frame images to determine the left ventricular contour of the target frame images; determining the apex point, the junction point between the left ventricular septum and the mitral valve, and the junction point between the left ventricular wall and the mitral valve in the left ventricular contour; and determining left ventricular parameters based on the left ventricular contour, the apex point, the junction point between the left ventricular septum and the mitral valve, and the junction point between the left ventricular wall and the mitral valve. The present invention balances the efficiency and accuracy of left ventricular measurement.

The invention relates to a positioning device (1) comprising a distal portion (8) adapted to be delivered through a defect, preferably through an opening in a ventricular or atrial septum. The positioning device comprises a mechanism for selectively dilating the distal portion (8) such that the distal portion can be deployed through the defect prior to dilation and, upon dilation, mechanically prevents retraction through the same defect. Thus, the positioning device (1) temporarily engages the defect site.

Methods, devices and program products are provided for managing a pacing therapy using an implantable medical device (IMD). The methods, devices and program products sense cardiac activity (CA) signals at electrodes located proximate to multiple left ventricular (LV) sites and a right ventricular (RV) site of the heart and utilizing one or more processors to measure activation times between the multiple LV sites and the RV site based on the CA signals. The processors program an order of activation for the multiple LV sites based on the activation times and identify an RV activation time and a septum activation time based on the CA signals. The processors calculate a septum to RV activation time (SRAT) based on the RV and septum activation times and program an AVSRAT delay based on the SRAT.

The invention relates to application of nervonic acid to preparation of a medicine for preventing and treating pressure overload pathological cardiac hypertrophy. Through in-vivo animal research, the inventor finds that nervonic acid can improve the left ventricular ejection fraction of the heart of a mouse with overload pressure, reduce the ventricular septum thickness and the left ventricular posterior wall thickness, reduce the ratio of the heart weight to the tibia length, reduce the cross sectional area of cardiac muscle cells, relieve cardiac fibrosis and reduce transcription of fibrosis related genes Tgfb1, Col1a1 and Col3a1. The nervonic acid is expected to become a candidate substance for preparing a medicine for preventing and treating the pressure overload pathological cardiac hypertrophy, and has a good clinical application prospect.

The invention provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension and application thereof, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition for treating pulmonary arterial hypertension is prepared from the following components in parts by weight: 5-7 parts of herba ephedrae, 7-9 parts of semen armeniacae amarae, 20-24 parts of gypsum, 5-7 parts of liquorice root, 9-11 parts of radix salviae miltiorrhizae, 0.8-1.2 parts of leech and 2.5-3.5 parts of radix notoginseng. According to the treatment principle of freeing lung, relieving asthma and promoting blood circulation to remove blood stasis, ephedra, apricot kernel, gypsum and licorice granules with the effects of freeing lung, clearing heat and relieving asthma are used as monarch drugs, and salvia miltiorrhiza, leech and pseudo-ginseng with the effects of promoting blood circulation to remove blood stasis are used as ministerial drugs for compatibility; the prepared traditional Chinese medicine composition can reduce the length ratio of the right ventricle to the left ventricle plus ventricular septum and the length ratio of the right ventricle to the tibia, inhibit right ventricular hypertrophy, repair pulmonary vascular injury and improve the pulmonary ventilation function, the cardio-pulmonary function and pulmonary arterial hypertension.

The present disclosure includes devices and techniques for threading one or more catheters to the apex or base of the right ventricle by transfemoral vein access to the right ventricle. The catheter can be passed through to turn upward, directed towards the mitral valve, by puncturing the ventricular septum into the left ventricle through the ventricular side or right side of the heart. From this entry point in the left ventricle, flail mitral valve leaflets can be sutured and tethered, pulled back into place, and re-attached with grounding anchors in the right ventricle, or embedded in the septal wall. The ventricular septal crossing technique may include passing a coaxial conduit through a first access conduit, where the first access conduit may act as a guide to direct an inner or second coaxial conduit toward a flail mitral valve leaflet.